Click on a star to see more details touch_app
Concepts for which Alexey Danilov MD has direct influence:
Prominent publications by Alexey Danilov, MD
KOL-Index: 2 This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal ...
|Known for |
Sll Hodgkin | Phase Event | Cycles Entospletinib | Cll Cells